Milstead S, Kienle P, Freudiger M, Blanc A, Fleury M. I had a dream in the clean room: from fragmented guidance to an international hazardous medicinal product list. J Pharm Clin. 2026;45(1):4–6. doi:10.1684/jpc.2026.0643.

Ovesen JL, Sammons D, Connor TH, MacKenzie BA, DeBord DG, Trout DB, et al. NIOSH list of hazardous drugs in healthcare settings, 2024. Cincinnati (OH): National Institute for Occupational Safety and Health; 2024. DHHS (NIOSH) Publication No. 2025-103. doi:10.26616/NIOSHPUB2025103.

Whittaker C, Ovesen JL, MacKenzie BA, Hartley T, Berry KA, Piacentino J. Procedures for developing the NIOSH list of hazardous drugs in healthcare settings. Cincinnati (OH): National Institute for Occupational Safety and Health; 2023. DHHS (NIOSH) Publication No. 2023-129. doi:10.26616/NIOSHPUB2023129.

United States Pharmacopeia. General Chapter <800>: Hazardous drugs—handling in healthcare settings. In: United States Pharmacopeia and National Formulary (USP–NF). Rockville (MD): United States Pharmacopeial Convention; 2020. doi:10.31003/USPNF_M7808_07_01.

National Association of Pharmacy Regulatory Authorities. Model standards for pharmacy compounding of hazardous sterile preparations. Ottawa (ON): National Association of Pharmacy Regulatory Authorities; 2016.

European Commission. Guidance for the safe management of hazardous medicinal products at work. Luxembourg: Publications Office of the European Union; 2023.

European Commission. Indicative list of hazardous medicinal products according to Article 18a of Directive 2004/37/EC. Off J Eur Union. 2025;C/2025/1150.

International Agency for Research on Cancer. IARC monographs on the identification of carcinogenic hazards to humans [Internet]. Lyon: International Agency for Research on Cancer; [cited 2026 Aug 1]. Available from: https://monographs.iarc.who.int/